Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HR-positive metastatic breast cancer after CDK4/6 inhibitors, drawn from the whole corpus: 29 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No trial has compared the sequence of oral SERD, pathway inhibitor and antibody-drug conjugate.
Whether to continue a CDK4/6 inhibitor after progression gives small gains and it is unclear for whom.
PIK3CA and ESR1 mutations often coexist and the combinations to treat both are unproven.
Hyperglycaemia, rash and diarrhoea limit pathway inhibitors in older patients.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
PFS HR 0.
PFS 16.
A milestone in how this cancer is treated.
PFS HR 0.